News

Ligand has reported the mutual termination of its collaboration and license agreement with Organon, which Ligand assumed in connection with its acquisition of Pharmacopeia in December 2008. Reportedly,

Depomed has reported a revenue of $11.6m for the second quarter ended June 30, 2009, a increase in comparison with $6.3m for the second quarter ended June 30,

AVI BioPharma has announced the impending strategic move to shift corporate headquarters and much of its leadership team to the greater Seattle area. The company plans to build

The Dow Chemical Company has reported a decrease in sales by 31% to $11.3 billion for the second quarter of 2009 from reported sales in the same period

Pfizer has reached an agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study. Kano State will dismiss

The US Food and Drug Administration (FDA) has approved Colcrys to treat acute flairs in patients with gout (a recurrent and painful form of arthritis) and patients with

Cornerstone has closed the strategic transaction with Chiesi. As a result of this transaction, the company has received an exclusive 10-year license for the US commercial rights to

FDA has approved United Therapeutics’ Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH), using the Tyvaso Inhalation System. Tyvaso is indicated to increase walk

ACT Biotech has reported the treatment of the first patients in a phase 2 clinical trial of Telatinib, in combination with standard-of-care chemotherapy, in the US and Spain.